SMi Group reports: fresh off the press – official agenda for Orphan Drugs and Rare Diseases taking place on 17 – 18 October in London Patients with rare diseases cannot continue to be overlooked because […]
The US Food and Drug Administration (FDA) has approved Dova Pharmaceuticals’ Doptelet drug for patients with thrombocytopenia, a reduction in the number of platelets in the blood, who are scheduled to undergo a medical or […]
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage […]
Israel-based pharmaceutical company Teva has announced confirmation that the US Food and Drugs Administration (FDA) will make a decision on the company’s migraine treatment fremanezumab by 16 September. The FDA had originally said it […]
Malvern Panalytical has launched its new Zetasizer Pro and Ultra systems, designed to help in decision-making within crucial analytical workflows associated to product development and quality control. Built on the heritage of the market-leading […]